A new treatment for multiple food allergies using a small molecule compound.
IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies
This study is testing a new daily pill called xanthopurpurin that could help lower allergy levels in people with multiple food allergies, making it easier and safer for them to manage their condition without having to avoid certain foods.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | General Nutraceutical Technology, LLC NIH-funded |
| Lab location | 1 site (Briarcliff Manor, UNITED STATES) |
| Project ID | NIH-10761370 on NIH RePORTER |
What this research studies
This research investigates a small molecule compound called xanthopurpurin, which has the potential to suppress IgE levels in patients with multiple food allergies. The study aims to develop a non-food restricted treatment that can effectively reduce elevated food-specific immunoglobulin E (sIgE), which is a major contributor to food allergy reactions. By utilizing a once-a-day oral dosage of this compound, the research seeks to provide a safer and more effective management option for individuals suffering from severe food allergies, including peanut and tree nut allergies. The approach is based on preliminary findings that suggest the compound is stable and has a favorable safety profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple food allergies, particularly those with peanut and tree nut allergies.
Not a fit: Patients with single food allergies or those who do not have elevated IgE levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that significantly improves the quality of life for patients with multiple food allergies.
How similar studies have performed: While the approach of using small molecule compounds for food allergies is relatively novel, preliminary data from similar research has shown promise in reducing IgE levels.
Where this research is happening
Briarcliff Manor, UNITED STATES
- General Nutraceutical Technology, LLC — Briarcliff Manor, United States (Active)
Researchers
- Principal investigator: Li, Xiu-Min — General Nutraceutical Technology, LLC
- Study coordinator: Li, Xiu-Min
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.